BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 9105568)

  • 1. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
    Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on low-density lipoprotein subclasses.
    Tilly-Kiesi M; Lappi M; Puolakka J; Luotola H; Pyörälä T; Taskinen MR
    Eur J Clin Invest; 1996 Dec; 26(12):1125-33. PubMed ID: 9013088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE; Lambrinoudaki IV; Panoulis CP; Papadias CA; Kouskouni EE; Creatsas GC
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens.
    Lahdenperä S; Puolakka J; Pyörälä T; Luotola H; Taskinen MR
    Atherosclerosis; 1996 May; 122(2):153-62. PubMed ID: 8769679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
    Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women.
    Al-Azzawi F; Wahab M; Sami S; Proudler AJ; Thompson J; Stevenson J
    Climacteric; 2004 Sep; 7(3):292-300. PubMed ID: 15669554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women.
    Sendag F; Karadadas N; Ozsener S; Bilgin O
    Arch Gynecol Obstet; 2002 Jan; 266(1):38-43. PubMed ID: 11998963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate.
    Lindgren R; Berg G; Hammar M; Larsson-Cohn U; Olsson AG
    Eur J Obstet Gynecol Reprod Biol; 1992 Dec; 47(3):213-21. PubMed ID: 1294408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National differences in lipid response to postmenopausal hormone replacement therapy.
    Ranta V; Oksanen H; Arrenbrecht S; Ylikorkala O
    Maturitas; 2002 Aug; 42(4):259-65. PubMed ID: 12191848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations.
    Whitcroft SI; Crook D; Marsh MS; Ellerington MC; Whitehead MI; Stevenson JC
    Obstet Gynecol; 1994 Aug; 84(2):222-6. PubMed ID: 8041534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women.
    Yilmazer M; Fenkci V; Fenkci S; Sonmezer M; Aktepe O; Altindis M; Kurtay G
    Maturitas; 2003 Dec; 46(4):245-53. PubMed ID: 14625121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, high-density lipoprotein subfractions and apolipoproteins in postmenopausal women in a two-year, randomized, double-blind, placebo-controlled trial.
    Kotecha PT; Godsland IF; Crook D; Stevenson JC
    Clin Endocrinol (Oxf); 2020 Apr; 92(4):303-311. PubMed ID: 31925799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
    Davidson MH; Maki KC; Marx P; Maki AC; Cyrowski MS; Nanavati N; Arce JC
    Arch Intern Med; 2000 Nov; 160(21):3315-25. PubMed ID: 11088095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate.
    Brinton EA
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):431-40. PubMed ID: 8630670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins.
    Tan KC; Shiu SW; Pang RW; Kung AW
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):187-94. PubMed ID: 9579231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.